Literature DB >> 18929737

Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives.

Pieter Stolk1, Sebastian Schneeweiss, Hubert G M Leufkens, Eibert R Heerdink.   

Abstract

BACKGROUND: We studied the impact of suspending oral contraceptive (OC) reimbursement in the Netherlands for women >21 years starting 1 January 2004. Discontinuation and switching patterns and the time course of the policy intervention's effects were determined. STUDY
DESIGN: The intervention cohort contained OC users on 1 January 2004; the control cohort users on 1 January 2003. Follow-up duration was 1 year. Discontinuation and switching patterns were assessed using relative risks (RR). Weekly refill fractions were calculated to determine the time course of the policy effects.
RESULTS: Our intervention cohort contained 434,917 OC users; the control cohort 489,904 users. When we excluded patients not affected by the policy intervention (i.e., all patients younger than 20 years), discontinuation rates were 15.3% (intervention cohort) and 12.3% (control cohort) (RR=1.24; 95% CI=1.23-1.26) and increased with age. Switching to cheaper OCs was greatest in the intervention cohort, particularly in the 40- to 44-year age group. Differences in cumulative refill fractions showed large variation over time.
CONCLUSION: The OC reimbursement intervention led to an increase in the discontinuation rate of 24%. The effect increased with older age groups. Considering the time course of effects of policy interventions is of critical importance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929737     DOI: 10.1016/j.contraception.2008.06.009

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

1.  Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.

Authors:  Tania Stafinski; Devidas Menon; Caroline Davis; Christopher McCabe
Journal:  Clinicoecon Outcomes Res       Date:  2011-08-30

Review 2.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

3.  Sources of European drug consumption data at a country level.

Authors:  Pili Ferrer; Elena Ballarín; Mònica Sabaté; Joan-Ramon Laporte; Marieke Schoonen; Marietta Rottenkolber; Joan Fortuny; Joerg Hasford; Iain Tatt; Luisa Ibáñez
Journal:  Int J Public Health       Date:  2014-05-30       Impact factor: 3.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.